Pradaxa - First New Oral Medication To Stop Blood Clotting In Over 50 Years Launched In Ireland Today Part 4

Boehringer  Ingelheim  continues  to  evaluate  the  efficacy and refuge of Pradaxa*  in  a inventory of thromboembolic virus provisos.

(3) Hartford, J., et al. Duloxetine by means of an SNRI Treatment for Generalized Anxiety Disorder: Results from a Placebo- and Active-Controlled Trial. Int Clin Psychopharmacol 2007: 22(3):167-74.

*Pradaxa be a map trademark **Please  refer to prescribe figures all for further information with close to clinical investigation #  Drug  interactions for Pradaxa*: anticoagulants and platelet aggregation agents;  amiodarone  (reduce  Pradaxa*  dose to 150mg); circumspection sad serious P - glycoprotein  inhibitors  (e.g.  verapamil,  clarithromycin)  or inducers (e.g. rifampicin, St John's wort). Contraindicated with quinidine References 1.  CHMP litter bureau 2. HIPE notes 2004, from Activity surrounded by Acute Public Hospitals in Ireland, 2004 Annual Report, published Dec 2007 3. Â  Geerts Â  WH,  Heit  JA,  Glagett  GP  et  al. Â  Prevention  of  Venous Thromboembolism.  Chest 2004; 126:338S-400S 4.  Reducing  the  risk  of venous thromboembolism in inpatients undergo surgery.  NICE clinical guideline 46 5.  Cohen  AT,  Tapson VF, Bergmann J-F et al.  Venous thromboembolism speculate and  prophylaxis  in  the  acute  break nest strictness background (ENDORSE study):  a multinational cross-sectional question Lancet 2008; 371(9610):387-394 6.  The  prevention  of  venous  thromboembolism  in hospitalised patients. Department of levitra professional, House of Commons levitra professional Committee buzz.  March 2005 7.  Stangier  J,  Rathgen  K,  Staehle  H  et  al. Â  The  pharmacokinetics, pharmacodynamics  and  tolerability  of  dabigatran  etexilate,  a modern oral direct  thrombin inhibitor, in in good levitra professional mannish subject.  Br J Clin Pharmacol. 2007; 64:292-303 8.  Stangier  J et al.  Pharmacokinetics and pharmacodynamics of the pilot oral  thrombin  inhibitor  dabigatran  in  levitra professionaly  elderly subjects.  Clin Pharmacokinet 2008; 47:47-59 9.  Blech  S  et  al. Â  The  metabolism  and disposition of the oral direct thrombin  inhibitor, dabigatran, in human.  Drug Metab Dispo. 2008; 36:386 -399 10. Â  Di  Nisio  M  et  al.  Direct thrombin inhibitors.  N Eng J Med. 2005; 353:1028-1040 11.  van Ryn J et al.  Dabigatran inhibit both genre a mass -bound and liquor leg thrombin  in  vitro: Â  Effects  compared  to heparin and hirudin.  Abstract Arteriosclerosis, Thrombosis and Vascular Biology (ATVB), Atlanta, GA, USA, May 2008 12.  Eriksson  BI,  Dahl  OE,  Kurth AA et al Oral dabigatran etexilate vs. Enoxaparin  for  the  avoidance of venous thromboembolism after unqualified knees changeover:  the  RE-MODEL  randomized  trial  J.Thromb  Haemost  2007; 5: 2178-2185 13.  Eriksson BI, Dahl OE, Rosenoir N et al.  Dabigatran etexilate equate with  enoxaparin  for  the  extended  prevention  of venous thromboembolism ensuing total hip replacement.  Lancet 2007; 370: 949-956 14. Summary of Product Characteristics for Pradaxa* March 2008 15. :miopharm.com About Boehringer Ingelheim The Â  Boehringer Â  Ingelheim  group  is  one  of  the  world's  20  foremost pharmaceutical people.  Headquartered in Ingelheim, Germany, it operate globally  with  144  affiliates  in  47  countries  and  more  than  38,000 workers. Â  Since  it be found in 1885, the privately-owned company savour been  committed  to  research,  escalating,  business and marketing fresh products of crucial curative appeal for human and veterinary tablets.

In  2007,  Boehringer Ingelheim situation net sale of 10.9 billion euro while spending  nearly  one  fifth  of net sales in its largest conglomerate segment, Prescription Â  Medicines, Â  on Â  research  and  advancement. Â  For  further information nearly worldwide clinical broken financier by Boehringer Ingelheim, oblige glob by:  Boehringer Ingelheim